OrbiMed Advisors CARL Position
ActiveOrbiMed Advisors held their position in CARLSMED, INC. (CARL) in Q4 2025, holding $15.5M worth of shares across 1,252,600 shares.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
About CARLSMED, INC.
Carlsmed, Inc. develops and operates a surgical platform for the treatment of complex adult spinal deformities that enables surgeons to harness clinical intelligence, advanced image recognition, and 3D printing technologies. Its product includes aprevo, a medical platform that makes surgical plans and devices tailored to the precise medical situation of every individual patient. It provides New Technology Add-On Payment (NTAP) reimbursement. The company was incorporated in 2018 and is based in Carlsbad, California.
Full company profile →Short Interest
2.6%
3.6 days to cover
OrbiMed Advisors CARL Position History
Frequently Asked Questions
Does OrbiMed Advisors own CARL?
Yes. As of Q4 2025, OrbiMed Advisors holds 1,252,600 shares of CARLSMED, INC. (CARL) valued at $15.5M. This data comes from their SEC 13F filing.
How many hedge funds own CARL?
1 specialist biotech hedge fund currently holds CARL. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy CARL?
OrbiMed Advisors's position in CARL was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's CARL position increasing or decreasing?
OrbiMed Advisors held their CARL position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CARLCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →